Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burk

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Biorxiv : the Preprint Server for Biology|December 3, 2025
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitisCaitlin M Burk, Duncan M Morgan, Jonathan N Glickman, et al.
The Journal of Allergy and Clinical Immunology|August 15, 2016
Early oral immunotherapy in peanut-allergic preschool children is safe and highly effectiveBrian P Vickery, Jelena P Berglund, Caitlin M Burk, et al.
Medical Physics|July 29, 2024
AAPM Task Group Report 299: Quality control in multi-energy computed tomographyRick R Layman, Shuai Leng, Kirsten L Boedeker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024)D F Woodward, A H-P Krauss, J Chen, et al.
British Journal of Pharmacology|August 22, 2000
Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compoundsD F Woodward, A H Krauss, J Chen, et al.
Nature Immunology|April 8, 2024
TCF1-LEF1 co-expression identifies a multipotent progenitor cell (T<sub>H</sub>2-MPP) across human allergic diseasesRadomir Kratchmarov, Sarah Djeddi, Garrett Dunlap, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
Survey of Ophthalmology|July 4, 2001
The pharmacology of bimatoprost (Lumigan)D F Woodward, A H Krauss, J Chen, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Biorxiv : the Preprint Server for Biology|December 3, 2025
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitisCaitlin M Burk, Duncan M Morgan, Jonathan N Glickman, et al.
The Journal of Allergy and Clinical Immunology|August 15, 2016
Early oral immunotherapy in peanut-allergic preschool children is safe and highly effectiveBrian P Vickery, Jelena P Berglund, Caitlin M Burk, et al.
Medical Physics|July 29, 2024
AAPM Task Group Report 299: Quality control in multi-energy computed tomographyRick R Layman, Shuai Leng, Kirsten L Boedeker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024)D F Woodward, A H-P Krauss, J Chen, et al.
British Journal of Pharmacology|August 22, 2000
Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compoundsD F Woodward, A H Krauss, J Chen, et al.
Nature Immunology|April 8, 2024
TCF1-LEF1 co-expression identifies a multipotent progenitor cell (T<sub>H</sub>2-MPP) across human allergic diseasesRadomir Kratchmarov, Sarah Djeddi, Garrett Dunlap, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
Survey of Ophthalmology|July 4, 2001
The pharmacology of bimatoprost (Lumigan)D F Woodward, A H Krauss, J Chen, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
Pageof 9